Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials.
about
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitisPeroxisome Proliferator-Activated Receptor- γ in Thyroid AutoimmunityPPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertaintyAdding pioglitazone to insulin containing regimens in type 2 diabetes: systematic review and meta-analysis.Efficacy and safety of thiazolidinediones in diabetes patients with renal impairment: a systematic review and meta-analysis.Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysisDefining and achieving treatment success in patients with type 2 diabetes mellitusPathogenesis and therapeutic approaches for non-alcoholic fatty liver diseaseManagement of cardiovascular risk factors with pioglitazone combination therapies in type 2 diabetes: an observational cohort study.Diabetes: glycaemic control in type 2 (drug treatments).Pharmacogenomics and pharmacogenetics of thiazolidinediones: role in diabetes and cardiovascular risk factors.The fixed combination of pioglitazone and metformin improves biomarkers of platelet function and chronic inflammation in type 2 diabetes patients: results from the PIOfix studyThe management of type 2 diabetic patients with hypoglycemic agentsIdealized PPARγ-Based Therapies: Lessons from Bench and BedsidePioglitazone in the treatment of type 2 diabetes: safety and efficacy reviewEffect of insulin sensitizer therapy on atherothrombotic and inflammatory profiles associated with insulin resistanceCardiovascular disease and glycemic control in type 2 diabetes: now that the dust is settling from large clinical trials.Safety and efficacy of rosiglitazone in the elderly diabetic patient.Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity or mortality? No.PPARγ and Its Role in Cardiovascular Diseases.Snail as a potential target molecule in cardiac fibrosis: paracrine action of endothelial cells on fibroblasts through snail and CTGF axis.Pioglitazone and risk of mortality in patients with type 2 diabetes: results from a European multidatabase cohort study.Cardiovascular effects of anti-diabetes drugs.Rosiglitazone inhibits vascular KATP channels and coronary vasodilation produced by isoprenaline.Therapeutic Implications of PPARgamma in Cardiovascular Diseases.
P2860
Q24625697-13ED0F53-85A9-4ADC-BBC7-C38D5A3928B9Q27022369-6EBFF68F-D0C4-4E5A-86CA-03B6DF4E6AECQ27024799-E7A86EDD-FFF4-4298-8372-3C29D10783BAQ33476850-A4ACA128-82FA-4314-B0E6-485A92968F0CQ33687578-9E1DB14A-06FB-4D6D-ADA9-40FBB89A1A1AQ33880174-4897FE68-5243-4334-ADBD-15E1E499B6AEQ34374314-744B9739-5B99-4ABE-BA18-0B54526E4532Q34449857-DA5A8FBE-6E72-4071-9F26-96DEE32781B6Q34592900-47D7950B-27D3-419C-8312-8253CDBF1B0BQ34829290-17482E56-C645-43A2-8241-D8CCB70090E8Q35039274-51A7238E-8591-44F1-85C2-13022FE1E74DQ35076036-48F140E7-36C0-4C3D-B5D4-79A327CC4A60Q35909101-F664345C-1F80-433B-9170-895EB11BB847Q36056207-E25497EB-FE3B-4816-9DF9-D732A7594A83Q36139056-2D07AD27-02BA-46F6-88F2-ECA4362BBD1DQ36397303-BA40CDC5-7225-4954-99E3-95230CDF26E1Q37023878-5A42214D-9431-42F6-A206-79F4A1C9B2B7Q37202144-F6082E77-F0FE-49FD-916C-A696442B7C86Q37624301-ADA3578E-D4AF-4178-A34F-D0F98E54D4D7Q37627571-8060C9DD-6434-4BEE-8E1E-505DDFA7EB49Q37636881-8C532F2A-E5CF-4BF1-99CC-5589FF1D6971Q38650414-D6F0B1C1-6188-4C5F-8977-8B701C21359FQ38857056-A63C02E5-721F-48A5-B879-B099F00F52F1Q39524834-F3A26B00-0512-4D51-8CBF-FEEC8967B581Q41855435-5841E7DB-4CF3-415E-8812-E37BD798256D
P2860
Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials.
description
2008 nî lūn-bûn
@nan
2008 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Pioglitazone and cardiovascula ...... of randomized clinical trials.
@ast
Pioglitazone and cardiovascula ...... of randomized clinical trials.
@en
Pioglitazone and cardiovascula ...... of randomized clinical trials.
@nl
type
label
Pioglitazone and cardiovascula ...... of randomized clinical trials.
@ast
Pioglitazone and cardiovascula ...... of randomized clinical trials.
@en
Pioglitazone and cardiovascula ...... of randomized clinical trials.
@nl
prefLabel
Pioglitazone and cardiovascula ...... of randomized clinical trials.
@ast
Pioglitazone and cardiovascula ...... of randomized clinical trials.
@en
Pioglitazone and cardiovascula ...... of randomized clinical trials.
@nl
P2093
P2860
P1476
Pioglitazone and cardiovascula ...... of randomized clinical trials.
@en
P2093
E Mannucci
G F Gensini
N Marchionni
P2860
P304
P356
10.1111/J.1463-1326.2008.00892.X
P577
2008-05-26T00:00:00Z